Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Portoles, J; Krisper, P; Choukroun, G; de Francisco, ALM.
Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients.
NEPHROL DIALYSIS TRANSPLANT. 2005; 20(S8): 13-17.
Doi: 10.1093/ndt/gfh1111
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Krisper Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Erythropoiesis-stimulating agents have dramatically changed the management of renal anaemia since their introduction almost 20 years ago. However, optimal dosing route and frequency are still a matter of debate. Intravenous application of recombinant human erythropoietin should be limited to haemodialysis patients and must be given three times weekly, as any reduction to this dosing frequency leads to a major increase in dose requirements. Administering recombinant human erythropoietin-beta once weekly via the subcutaneous route is effective. If conversion from the subcutaneous to the intravenous route is required, dose requirements for recombinant human erythropoietin therapy remain a subject of discussion.
- Find related publications in this database (using NLM MeSH Indexing)
- Anemia - drug therapy
- Chronic Disease - drug therapy
- Drug Administration Schedule - drug therapy
- Erythropoiesis - drug effects
- Erythropoietin, Recombinant - administration and dosage
- Humans - administration and dosage
- Kidney Diseases - complications
- Red-Cell Aplasia, Pure - etiology
- Renal Dialysis - etiology
- Find related publications in this database (Keywords)
- chronic kidney disease
- doses and routes
- erythropoietin
- renal anaemia